Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Profit After Tax (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Profit After Tax for 16 consecutive years, with $28.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Profit After Tax rose 116.12% year-over-year to $28.2 million, compared with a TTM value of $233.6 million through Dec 2025, up 136.3%, and an annual FY2025 reading of $30.1 million, up 105.02% over the prior year.
  • Profit After Tax was $28.2 million for Q4 2025 at Arrowhead Pharmaceuticals, up from $16.1 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $367.9 million in Q1 2025 and bottomed at -$178.7 million in Q2 2025.
  • Average Profit After Tax over 5 years is -$52.3 million, with a median of -$67.7 million recorded in 2021.
  • The sharpest move saw Profit After Tax tumbled 366.37% in 2024, then surged 389.67% in 2025.
  • Year by year, Profit After Tax stood at -$62.9 million in 2021, then soared by 33.5% to -$41.8 million in 2022, then crashed by 223.78% to -$135.4 million in 2023, then dropped by 29.43% to -$175.2 million in 2024, then soared by 116.12% to $28.2 million in 2025.
  • Business Quant data shows Profit After Tax for ARWR at $28.2 million in Q4 2025, $16.1 million in Q3 2025, and -$178.7 million in Q2 2025.